Preclinical investigations suggest that the neuropeptide substance P might
be involved in the etiopathology of pain, depression, and anxiety. In a rec
ent study, the substance P receptor antagonist MK-869 showed antidepressant
and anxiolytic activity in depressed outpatients which was comparable to a
standard SSRI. The MK-869 was well tolerated. Although these findings are
promising, further studies are necessary to prove the hypothesis that subst
ance P receptor antagonists represent a new class of antidepressants or anx
iolytics. Respective studies are currently underway.